News
Company News: Curetis Announces Financial Results for the First Three Months of 2019
– Total year-on-year revenue growth of approximately 45%
– Successful implementation of corporate re-organization and significant reduction of cost base
– Exclusive pan-European distribution partnership with A. Menarini Diagnostics
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first three months ended March 31, 2019, and provided a business update for 2019. Read more…
Company News: MCG motion capture GmbH Founded by Seasoned Medtech and Digital Health Entrepreneurs
— Unparalleled expertise in precision motion analysis and digital care
— Novel motion biomarker solutions for, pharma, healthcare, OHM and sports
A team of seasoned European healthcare entrepreneurs today announced the foundation of MCG motion capture GmbH (MCG), the world’s first precision motion analysis and digital care company. The team combines decades of expertise in the medtech, digital health and biopharmaceutical industry, including big data integration, analysis for decision support, and long-standing experience in clinical trials as well as the regulatory and reimbursement landscape in Europe and the U.S. Read more…
Company News: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019
— Strain-typing and AMR detection of clinical isolates based on ARESdb
— Set-up of own NGS service laboratory in Vienna, Austria
Ares Genetics GmbH (Ares Genetics), a Curetis Group Company (Curetis N.V.; EURONEXT: CURE), today announced the introduction of new service offerings in molecular microbiology at the upcoming 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place in Amsterdam, the Netherlands, on April 13-16, 2019. Read more…
Company News: Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019
– Launched Unyvero System and Unyvero LRT Cartridge in the U.S.
– Increased revenues to EUR 1.4 million in 2018
– Raised EUR 19.5 million additional funding
– Revised focus and strategy
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the financial results for the twelve months ended December 31, 2018, and provided an updated guidance for 2019. Read more…